WO2011090297A3 - 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도 - Google Patents

항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도 Download PDF

Info

Publication number
WO2011090297A3
WO2011090297A3 PCT/KR2011/000329 KR2011000329W WO2011090297A3 WO 2011090297 A3 WO2011090297 A3 WO 2011090297A3 KR 2011000329 W KR2011000329 W KR 2011000329W WO 2011090297 A3 WO2011090297 A3 WO 2011090297A3
Authority
WO
WIPO (PCT)
Prior art keywords
mdm2
stem cell
adult stem
human adult
expressing anti
Prior art date
Application number
PCT/KR2011/000329
Other languages
English (en)
French (fr)
Other versions
WO2011090297A2 (ko
Inventor
박국인
김일선
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2011090297A2 publication Critical patent/WO2011090297A2/ko
Publication of WO2011090297A3 publication Critical patent/WO2011090297A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 항-MDM2를 암호화하는 핵산을 포함하는 인간의 신경줄기세포 및 이를 포함한 암 치료용 약제학적 조성물을 제공한다. 본 발명의 항-MDM2를 암호화하는 핵산을 포함하는 인간의 신경줄기세포는 세포독성을 유발하지 않으면서, 생체 내에서 항-MDM2를 분비하여 비정상 세포의 아폽토시스를 유발하므로 암 등 세포과다증식 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2011/000329 2010-01-21 2011-01-17 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도 WO2011090297A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100005723A KR101220516B1 (ko) 2010-01-21 2010-01-21 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
KR10-2010-0005723 2010-01-21

Publications (2)

Publication Number Publication Date
WO2011090297A2 WO2011090297A2 (ko) 2011-07-28
WO2011090297A3 true WO2011090297A3 (ko) 2011-12-29

Family

ID=44307376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000329 WO2011090297A2 (ko) 2010-01-21 2011-01-17 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도

Country Status (2)

Country Link
KR (1) KR101220516B1 (ko)
WO (1) WO2011090297A2 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 ***交联的和硫醚交联的拟肽大环化合物
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002642A1 (en) * 1994-07-20 1996-02-01 University Of Dundee INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002642A1 (en) * 1994-07-20 1996-02-01 University Of Dundee INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENE ET AL.: "Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface", MOLECULAR CANCER RESEARCH, vol. 2, 2004, pages 20 - 28 *
MENG ET AL.: "Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis Type VII Mouse", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 74, 2003, pages 266 - 277, XP002997245 *

Also Published As

Publication number Publication date
WO2011090297A2 (ko) 2011-07-28
KR20110085765A (ko) 2011-07-27
KR101220516B1 (ko) 2013-01-10

Similar Documents

Publication Publication Date Title
WO2011090297A3 (ko) 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
UA115887C2 (uk) АМІНОЗАМІЩЕНІ ІМІДАЗО[1,2-а]ПІРИДИНКАРБОКСАМІДИ І ЇХ ЗАСТОСУВАННЯ
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MY152033A (en) Anti-siglec-15 antibody
WO2012062925A3 (en) Compounds and methods for treating pain
EP2432483A4 (en) COMPOSITION WITH THE CLEANED EXTRACT OF BEE POISON FOR THE PREVENTION AND TREATMENT OF DEGENERATIVE BRAIN DISEASES
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
WO2012047951A3 (en) Human lung stem cells and uses thereof
IL251543A0 (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
WO2014210037A3 (en) A composition of mesenchymal stem cells
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
WO2013174774A3 (en) Cosmetic compositions comprising magnetosomes and uses thereof
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MY150931A (en) Substituted oxazolidinones and their use
IL238411A0 (en) Compositions of medicinal plants for the prevention and treatment of tnf-α related diseases
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
WO2011055931A3 (ko) 인플루엔자 바이러스 유래 질병의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11734846

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11734846

Country of ref document: EP

Kind code of ref document: A2